

Clinical Trials Registry at EDA

SN	Submission Date	Study Code (Specified as per the submitted protocol)	Sponsor/ CRO	Study Title	Study Phase (I, II, III, or IV)	Sites Activation Date “At which the clinical trials will be conducted in Egypt”	Status/Date: - Approved - Recruiting - Recruitment completion - Completed - Withdrawn - Suspended - Terminated	Conditions / Therapeutic Area	Interventions Used IMPs & its type (Biological, Pharmaceutical, Innovative, Herbal, or medical device)
1-	27/12/2018	M15-991	Sponsor: Abbvie	A multi-center, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of Risankizumab in subjects with moderately to severely active Crohn's disease who failed prior biologic treatment	III	1- CRC, faculty of medicine, Alexandria university 2- CRC, faculty of medicine, Alexandria university 3- Faculty of medicine, Cairo university 4- MASRI-CRC, Ain Shams University	Approved 26/03/2019 Completed 03/11/2021	moderately to severely active Crohn's disease who failed prior biologic treatment	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						5- National hepatology and tropical medicine institute 6- Faculty of medicine, Zagazig university			
2-	27\12\2018	M16-000	Sponsor: Abbvie	A Multicenter, Randomized, Double-Blind, Placebo- Controlled 52- Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease who respond to induction treatment in M16-006 or M15-991 ; or	III	1- Two sites at Faculty of Medicine, CRC, Alexandria University	Approved 26/03/2019 Recruitment completion	Crohn's disease	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				completed M15-989					
3-	28/02/2019	M16-066	Sponsor: Abbvie	A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis	III	1- Faculty of medicine, CRC, Alexandria University 2- CRC, Alexandria University 3- Air Force Specialized Hospital Research 4- National Liver Institute, Menoufia University	Approved 10/06/2019 Recruitment completion	Ulcerative Colitis	(Biological) Risankizumab
4-	28/02/2019	M16-067	Sponsor: Abbvie	Multicenter randomized double-blind placebo-controlled induction study to evaluate the efficacy and safety of Risankizumab in subjects with	III	1- CRC, faculty of medicine, Alexandria University 2- National Liver Institute, Menoufia University	Approved 10/06/2019 Completed: 30/11/2023	Active ulcerative colitis.	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				moderately to severely active ulcerative colitis.		3- Air Force Specialized Hospital 4- Faculty of Medicine, CRC, Alexandria University			
5-	07/05/2019	QGE031	Sponsor: Novartis	A Multicenter, Randomized, double-blind active and placebo-controlled study to investigate the efficacy and safety of Ligelizumab in the treatment of chronic spontaneous urticaria in adolescents and adults in adequately controlled with H1 antihistamines	III	1- Faculty of medicine, Alexandria university 2- Faculty of medicine, Ain Shams University	Withdrawn 31/08/2020	Chronic spontaneous Urticaria	(Biological) Ligelizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

6-	18/09/2019	ARTEMI S-DM "LPS1539 6"	Sponsor: SANOFI	A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin	IV	1- Faculty of medicine, Alexandria university 2- CRC, Alexandria university 3- GOTH 4- Faculty of medicine, Menoufia university 5- Faculty of medicine, Ain Shams university	Approved 09/02/2020 Withdrawn	Type 2 diabetes mellitus	(Biological) Insulin glargine "Toujeo"
7-	18/11/2019	STAND	Sponsor: Novartis	A phase II, multicenter, randomized, open label, two arm study comparing the effect of crizanlizumab+ SOC alone on renal function in sickle cell disease patients ≥ 16 years	II	1- Abu El Resh Children Hospital	Approved 05/05/2020 Withdrawn 03/08/2021	Sickle cell anemia	(Biological) Crizanlizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				with chronic kidney disease due to sickle cell nephropathy					
8-	24/03/2020	STEAD FAST	Sponsor: Novartis	A Phase III, multicenter, double-blind study to assess efficacy and safety of two doses of crizanlizumab vs placebo with or without hydroxyurea / hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with vaso-occlusive crisis	III	1- Faculty of medicine, Alexandria university 2- Faculty of medicine, Ain Shams university	Approved 20/02/2020 Withdrawn 03/08/2021	Sickle cell anemia	(Biological) Crizanlizumab
9-	30/03/2020	WA40404	Sponsor: Roche	A Phase III b Multicenter, Randomized, double-blind, Placebo-controlled	IIIb	1- Sayed Galal Hospital 2- Faculty of medicine,	Approved 23/08/2020 Withdrawn 25/08/2021	Primary progressive multiple sclerosis	(Biological) Ocrelizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive Multiple Sclerosis		Alexandria university 3- CRC, MASRI, Ain Shams University			
10-	14/09/2020	1368-0025	Sponsor: Boehringer Ingelheim	Open label long term extension study to assess the safety and efficacy of BI655130 treatment in patients with generalized pustular psoriasis	IIb	1- Dermatology department, faculty of medicine, Alexandria university hospital	Approved 18/05/2021 Withdrawn 31/10/2021	Generalized pustular psoriasis	(Biological) Spesolimab
11-	21/09/2020	05-Gam-COVID-Vac-2020	Sponsor: Russian Direct Investment Fund (RDIF)	A Phase III, randomized, double blind, placebo-controlled trial to evaluate immunogenicity and safety of the Gam-COVID-Vac combined vector vaccine in	III	1- National liver institute, Menoufia university 2- CRC, faculty of medicine, Alexandria university 3- CRC, MASRI, Ain	Withdrawn 12/06/2022	COVID-19 prophylaxis	(Biological) Russian Gam-COVID-Vac Combine vector vaccine

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				prophylactic treatment for SARS-COV-2 infection in Egypt		Shams University			
12-	22/09/2020	CNBG202 0003SQ	Sponsor: China National Biotec Group company limited Wuhan institute of biological products Co. Ltd Beijin institute of biological products Co.Ltd	Multicenter, Randomized, Double blind, parallel placebo controlled, Phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of Inactivated SARS- COV-2 Vaccines in healthy population aged 18 years old and above	III	1- Vacsera Health care facility 2- Ktameya medical center	Approved 28/03/2022 Completed 31/07/2022	COVID-19 Prophylaxis	(Biological) Inactivated SARS- COV-1 Vaccine
13-	13/04/2021	D910DC0 0001 (Emerald- 2)	Sponsor: AstraZene ca	A phase 3 randomized double blind placebo controlled multicentre study	III	1- CRC, Faculty of medicine, Alexandria University hospital	Approved 12/12/2021	Hepatocellul ar carcinoma patients at high risk of recurrence	(Biological) Durvalumab\ Bevacizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			CRO: IQVIA	of durvalumab monotherapy or in combination with bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation		2- National Liver Institute- Menoufia University 3- National Hepatology & Tropical Medicine Research Institute 4- Air Force specialized Hospital 5- Faculty of medicine, Assuit University	Recruitment completion	after curative hepatic resection or ablation	
14-	19/05/2021	01- Sputnik- Light- 2021	Sponsor: Human vaccine LLC (Global), Russian ministry of healthcare	A phase III, randomized, double-blind, placebo-controlled international multi- site clinical trial in parallel assignment to evaluate efficacy,	III	1- National hepatology and tropical medicine center 2- Katemeya medical center	Approved 24/08/2021 Completion of study visit 31/08/2022	COVID-19 Prophylaxis	(Biological) Sputnik Light vector vaccine

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			– Gamalya (Local) CRO: PDC	immunogenicity and safety of the Sputnik Light vector vaccine in adults in the SARS-Cov-2 infection prophylactic treatment					
15-	25/05/2021	KATE-3	Sponsor: Roche	A randomized, multi-center, double blind, placebo-controlled phase III study of the efficacy and safety of Trastuzumab Emtansine in combination with Atezolizumab or placebo in Pts with HER2-positive and PD-L1- positive locally advanced or metastatic breast cancer who have received prior	III	1- Faculty of medicine, Kasr Al-Ainy hospital 2- Shefaa Al- Orman hospital 3- Baheya Hospital	Approved 05/12/2021 Withdrawn 19/12/2022	HER2- positive and PD-L1- positive locally advanced or metastatic breast cancer	(Biological) Trastuzumab Emtansine/ Atezolizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Trastuzumab + Atezolizumab and Taxane- based therapy					
16-	27/05/2021	CAIN457 P12301	Sponsor: Novartis	A randomized, double blind, placebo-controlled, parallel group, phase III multi- center study of intravenous Secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active ankylosis spondylitis of non- radiographic axial spondylo arthritis	III	1-CRC, Faculty of medicine, Alexandrian university	Withdrawn 03/11/2021	Active ankylosing spondylitis	(Biological) Secukinumab
17-	05/08/2021	TG2101V 01	Sponsor:	A Global, Multi- Center, Randomized,	III	1-National Hepatology and Tropical	Withdrawn 16/01/2022	COVID-19 Prophylaxis	(Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			Livzon mabpharm Inc.	Double-Blind, Placebo- Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older",		Medicine Research Institute (NHTMRI)			Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
18-	18/08/2021	MO42541	Sponsor: Roche	A phase III, open label, randomized study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with Atezolizumab and Bevacizumab	III	1- Air force specialized hospital	Approved 02/02/2022 Recruitment completion	Hepatocellul ar carcinoma	(Biological) Atezolizumab/ Lenvatinib/ Sorafenib

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

19-	02/09/2021	COVID_VACC_1	Sponsor: National research center CRO: Clinmax	A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated SARS-CoV-2 Vaccine Against COVID-19 in Healthy Adults	I	1- National research center	Approved 09/11/2021 Suspended 09/12/2021	Covid-19 Prophylaxis	(Biological) Inactivated SARS-CoV-2 Vaccine
20-	17/01/2022	SPHINX-EGYPT SPHINX2 2122020	Sponsor: - EVA PHARMA - VSVRI - supreme council of university hospitals - Ministry of higher education and scientific research CRO: Dataclin	Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of SARS-CoV-2 Infection (COVID-19)	I	1- Al-Manial specialized university Hospital, Cairo university hospitals	Approved 03/02/2022 Database lock 26/09/2023	Covid-19 Prophylaxis	(Biological) EgyVax

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

21-	04/11/2021	GBT2104-131	Sponsor: Global blood therapeutics Inc. \ Pfizer CRO: MCT	A randomized double blinded placebo controlled multicentre study to access the safety and efficacy of Inclacumab in participants with sickle cell disease experiencing Vaso- occlusive crisis	III	1- Faculty of medicine, Mansoura University 2- Faculty of medicine, Zagazig University 3- MASRI- CRC, Faculty of medicine, Ain Shams University hospital 4- CRC, Alexandria University 5- Pediatric hematology department, Alexandria University 6- CRC, faculty of medicine, Cairo University, Abo	Approved 14/06/2022 Completed: 30/05/2025	sickle cell disease patients with Vaso- occlusive crisis	(Biological) Inclacumab
-----	------------	-------------	--	---	-----	--	--	---	--------------------------------

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						El-Resh Hospital 7- CRC, Cairo University 8- Hematology department, Cairo University hospital			
22-	04/01/2022	GBT2104-132	Sponsor: Global blood therapeuti cs Inc.\ Pfizer CRO: MCT	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re- admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises (GBT-132)	III	1- Faculty of medicine, Mansoura University 2-. Faculty of medicine, Zagazig University 3- MASRI, CRC, Ain Shams University 4- Hematology unit, Internal medical department, CRC, faculty of medicine Alexandria	Approved 14/06/2022 Withdrawn 29/06/2023	Sickle cell disease patients with Vaso- occlusive crisis	(Biological) Inclacumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						University hospital 5- Hematology department, Alexandria University hospital 6- Cairo University, Abo El-Resh Hospital 7- CRC, Cairo University 8- Cairo University, Hematology department.			
23-	28/11/2021	GBT2104-133	Sponsor: Global blood therapeuti cs Inc.\ Pfizer CRO: MCT	An Open-label Extension Study to Evaluate the Long- term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an	III	1- Faculty of medicine, Mansoura University 2- Faculty of medicine, Zagazig University 3- MASRI, CRC, Ain	Approved 14/06/2022 Withdrawn 17/12/2023	sickle cell disease	(Biological) Inclacumab/ Placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal



				Inclacumab Clinical Trial		Shams University 4- Hematology unit, Internal medical department, CRC, faculty of medicine Alexandria University hospital 5- Hematology department, Alexandria University hospital 6- Cairo University, Abo El-Resh Hospital 7- CRC, Cairo University 8- Cairo University, Hematology department.			
--	--	--	--	------------------------------	--	--	--	--	--

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

24-	08\06\2022	Consonance-MN39159	Sponsor: F. HOFFMANN-LA ROCHE LTD CRO: Roche Egypt LLC & IQVIA (for monitoring activities only)	An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis	III	1- CRC, Faculty of Medicine, Alexandria university, CRC 2- MASRI-CRC, faculty of medicine, Ain Shams university hospital	Approved 20/09/2022 Recruitment completion	Progressive multiple sclerosis	(Biological) Ocrelizumab
25-	09\02\2022	20200404 (IMBCAM)	Sponsor: Institute of Medical Biology Chinese Academy of Medical Sciences	A randomized double-blinded placebo-controlled Phase III clinical trial of SARS-COV-2 vaccine inactivated (Vero cell) in adult aged 18 years and above	III	1- Katameya Medical Center 2- National Hepatology and tropical medicine institute	Withdrawn 24/02/2022	Covid-19 Prophylaxis	(Biological) Inactivated SARS-COV-2 vaccine

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			CRO: PDC						
26-	10/05/2022	TRISTAR DS- 0135-0347	Sponsor: Boehringer Ingelheim CRO: MCT	The TRISTARDS trial -Thrombolys is Therapy for ARDS A Phase IIb/III operationally seamless, open- label, randomized, sequential, parallel- group adaptive study to evaluate the efficacy and safety of daily intravenous alteplase treatment given up to 5 days on top of standard of care (SOC) compared with SOC alone, in patients with acute respiratory distress syndrome (ARDS)	IIb/III	1- National Hepatology and Tropical Medicine Research Institute 2- Abbasia Fever Hospital 3- Imbaba Fever Hospital	Withdrawn 20/07/2022	Respiratory distress syndrome (ARDS) triggered by COVID-19	(Biological) Alteplase

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				triggered by COVID-19.					
27-	14/08/2022	CAIN457 A2310	Sponsor: Novartis CRO: MCT	A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous Secukinumab compared to placebo and etanercept (in a single blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis	III	1- CRC, Faculty of Medicine, Alexandria university hospital 2- Dermatology department, faculty of Medicine, Ain Shams University hospital	Approved 04/12/2022 Early terminated by sponsor 31/03/2023	Treatments of severe chronic plaque psoriasis	(Biological) Secukinumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

28-	08/11/2022	SCTV01E -MRCT-1	Sponsor: Sinocelltech CRO: PDC	A randomized double blind positive controlled phase III clinical trial to evaluate the efficacy and safety of SCTV01E (a covid- 19alpha/beta/delta/ omicron variants s- trimmer vaccine) in population previously unvaccinated with COVID-19 vaccine and aged ≥ 18	III	1- Katemya Medical Center 2- Egyptian Liver research institute and hospital	Withdrawn 14/01/2023	COVID-19 prophylaxis	(Biological) SCTV 01E (a covid-19 alpha/beta/delta/ omicron variants s- trimmer vaccine) (Biological)
29-	06/06/2023	FUZION CNT0195 9CRD	Sponsor: Janssen CRO: MCT	A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's	III	1- National Hepatology Tropical Medicine Research Institute 2- CRC, faculty of medicine Alexandria university	Approved 13/08/2023 Recruiting	Fistulizing perianal Crohn's disease	Guselkumab (Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Disease “FUZION CD”		hospital, (two sites) 3- Department of internal medicine, El Kasr Al Aini, Cairo University 4- MASRI CRC, faculty of medicine, Ain Shams University Hospital			
30-	14/05/2023	MP- ADA1-01	Sponsor: Minaphar m CRO: CRS Clinical Research Services Berlin GmbH	A Phase I, randomized, double-blind, 2- arm, parallel group trial to compare pharmacokinetics of Adessia with EU-authorized Humira in healthy male and female participants”	I	1- CRS clinical research services, Berlin GmbH 2- CRS clinical research services, Mannheim GmbH	Approved 10/08/2023 Completed	Inflammatory disease (Biosimilar to Humira)	Adessia (Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

31-	04/05/2023	MOM-M281-006	Sponsor: Janssen CRO: MCT	Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension"	II/III	1- National Cancer Institute, Cairo university 2- Oncology center, Mansoura University Hospital 3- Department of internal medicine, Al Kasr al Eini, Cairo university 4- Naser institute hospital for research and treatment 5- CRC, faculty of medicine, Alexandria university Hospital 6- CRC, faculty of medicine, Ain shams university Hospital	Approved 19/07/2023 Early Terminated by the sponsor 21/02/2025	Warm Autoimmune Hemolytic Anemia	M281 (Biological)
-----	------------	--------------	--	---	--------	--	--	----------------------------------	--------------------------

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

32-	09\10\2023 shift to amendment submission 26\12\2023	EMERALD-3) D910VC0 0001	Sponsor: AstraZeneca CRO: IQVIA	A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)	III	1- Air Force specialized hospital 2- Oncology department, Faculty of medicine, Alex University 3- Egyptian liver Hospital National Hepatology and Tropical Medicine Research Institute (NHTMRI) 4- Shifa El orman Hospital	Approved 08/02/2024 Recruiting	Locoregional Hepatocellular Carcinoma	(Biological) Durvalumab / Tremelimumab/ Lenvatinib /TACE
33-	not submitted officially	CERE- CAP	Investigator- initiated	Efficacy of Cerebrolysin as an adjuvant therapy following mechanical thrombectomy in	III	1- Neurology and psychiatry department, Ain Shams University Hospital	Terminated (by EDA) (15/01/2024)	occlusion stroke	(Biological) CEREBROLYSIN solution for IM or IV injection/ concentrate for

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				patients with large vessels occlusion stroke					solution for I.V. infusion
34-	14/12/2023	BCD-178	Sponsor: JSC BIOCAD CRO: Dataclin	A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer	III	1- Faculty of Medicine, Alexandria University 2- Faculty of Medicine, Cairo University	Approved: 22/04/2024 Withdrawn: 25\12\2024	Her-2 positive breast cancer	Biological BCD-178
35-	08/01/2024	SerpinPc 102	Sponsor: Apcintex CRO: MCT	A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (AP-0102)	IIb	1- Ain Shams University Medical Research Institute (MASRI)	Conditional Approved 13/06/2024 Final Approval 31/10/2024 Withdrawn: 16/01/2025	Hemophilia A or Moderately Severe to Severe Hemophilia B	Biological SerpinPC 102

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

36-	08/01/2024	SerpinPC103	Sponsor: Apcintex CRO: MCT	A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Hemophilia B with Inhibitors (AP-0103)	Iib	1- Ain Shams University Medical Research Institute (MASRI)	Conditional Approved 13/06/2024 Final Approval 31/10/2024 Withdrawn: 16/01/2025	Hemophilia B with Inhibitors	Biological Serpin PC 103
37-	08/02/2024	D9185C00001” TILIA’	Sponsor: AstraZenca CRO: IQVIA	A Phase III, Multicenter, Randomized, Double-bind, Parallel-group, Placebo-Controlled study to evaluate the efficacy and safety of Tozoralimab (MEDI3506) in patients hospitalized for viral lung infection requiring supplemental oxygen	III	1-Air Force specialized Hospital 2-Ain Shams University Medical Research Institute (MASRI-CRC) 3-CRC, Alexandria University Hospital	Approved: 04/08/2024 Withdrawn: 30/01/2025	Patients hospitalized for viral lung infection	Biological Tozoralimab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

38-	16/01/2025	GA45329- Ametrine 1	Sponsor: Roche	A Phase III, Multicenter, Double-Blind, Placebo- Controlled, Treat- Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 In Patients with Moderately to Severely Active Ulcerative Colitis	III	1- Clinical Research Center, Internal Medicine Faculty of Medicine, Alexandria University	Approved: 10/03/2025 Withdrawn: 10/09/2025	Patients with Moderately to Severely Active Ulcerative Colitis	Biological RO7790121
39-	16/01/2025	GA45330- Ametrine 2	Sponsor: Roche	A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy with RO7790121 In Patients with Moderately to	III	1- Clinical Research Center, Internal Medicine Faculty of Medicine, Alexandria University	Approved: 10/03/2025 Withdrawn: 10/09/2025	Patients with Moderately to Severely Active Ulcerative Colitis	Biological RO7790121

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Severely Active Ulcerative Colitis					
40-	11/05/2025	GA45331	Sponsor: Roche	A Phase III Multicenter Double Blind Placebo Controlled Treat through study to assess the efficacy and safety of Induction and Maintenance therapy with RO7790121 in patients with moderately to severely active Crohn's disease	III	1-Clinical Research Center, Faculty of Medicine, Alexandria University Hospital 2-Air Force Specialized Hospital 3-National Liver Institute, Menoufya University	Approved: 01/06/2025	Crohn's Disease	Biological RO7790121
41-	17/12/2020	CEGA230 B2404	Sponsor: Novartis CRO: MCT	A Phase IV Multicenter Open Label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of	IV	1-Cairo University, Al Mounira Children Hospital, Pediatric Hepatology Unit.	Approved 12/04/2021 Recruiting	Fascioliasis	(Pharmaceutical) Triclabandazole (Egaten)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Egaten (Triclabandazole) in Patients 6 Years of Age or Older with Fascioliasis (Egaten)		2-Alexandria University, Faculty of Medicine, Clinical Research Center.			
42-	22/12/2020	CLEE011 A3201C RIGHT Choice	Sponsor: Novartis CRO: MCT	A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate with Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients with Hormone Receptor- Positive/HER2- Negative Inoperable Locally Advanced or Metastatic Breast	II	1-Ain Shams University, Faculty of Medicine, Clinical Research Center, (MASRI – CRC) 2-Baheya Hospital Research Center 3-Cairo University, NEMROCK 4-Nasser Institute Cancer Center	Approved 14/10/2021 Completed 08/01/2023	HER-2 Negative Breast Cancer	(Pharmaceutical) Ribociclib Plus Goserelin / Physician Choice Chemotherapy

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Cancer - RIGHT Choice Study					
43-	24/10/2021	M14-430	Sponsor: Abbvie	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14- 431 or M14-433	III	1-Air Force Specialized Hospital 2-National Liver Institute Menoufiya University 3-Alexandria University, Faculty of Medicine, Clinical Research Center. 4-Ain Shams University, Faculty of Medicine, Clinical Research Center (MASRI- CRC).	Approved 07/07/2022 Recruitment Completion	Chron's Disease	(Pharmaceutical) Upadacitinib/ matching placebo
44-	26/10/2021	BO40336 ALINA	Sponsor: Roche	A Phase III, Open- Label, Randomized Study to Evaluate the Efficacy and	III	1- Cairo University, Kasr Al Eini, Center of Radiation	Approved 16/03/2022	Lung Cancer	(Pharmaceutical)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors $\geq$ 4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer		Oncology and Nuclear Medicine.	Recruitment Completion		Alectinib / Platinum based Chemotherapy
45-	12/12/2021	Cl_Tr_17 122019 MIRACL E-ALA	Sponsor: EVA Pharma CRO: MARC	A Multicenter, Interventional, Two-Arm, Parallel-Group, Randomized, Double-Blinded, Placebo-Controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the	IV	1- Alexandria University Hospital, Diabetes, Metabolism, and Lipidology Unit, Department of Internal Medicine.	Approved 12/10/2022 Completed 11/12/2024	Treatment of Symptomatic Diabetic Polyneuropathy	(Pharmaceutical) Alpha-Lipoic Acid (Thiotacid)/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Treatment of Patients with Symptomatic Diabetic Polyneuropathy in Egypt		2- Ain Shams University Hospital 3- Menoufiya University Hospital 4- Mansoura University, Intrinsic Specialized Hospital. 5- Beni-Suef University Hospital, Diabetes and Endocrinology Unit.			
46-	12/12/2021	MK4482-013 MOVE-Ahead	Sponsor: MSD	A Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19	III	1-Ain Shams University Clinical Research Center (MASRI-CRC). 2-Air Force Specialized Hospital. 3-National Hepatology and	Approved 18/01/2022 Completed 16/11/2022	Prophylaxis of COVID-19	(Pharmaceutical) Molnupiravir/ matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				(Laboratory Confirmed SARS- COV 2 Infection with Symptoms) in Adults.		Tropical Medicine Research Institute. 4-Imbaba Fever Hospital. 5-National Center for Allergies and Chest Imbaba			
47-	30/03/2022	GBT440- 032	Sponsor: GBT (Subsidiar y of Pfizer) CRO: CTI	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)	III	1-Ain Shams University Clinical Research Center (MASRI-CRC). 2-Alexandria University Clinical Research Center. 3- Al Mounira Children Hospital, Cairo University, 4-Zagazig University Hospital,	Approved 31/07/2022 IMP Dosing Pause 02/05/2024 Early Termination by the sponsor 29/09/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor/ matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						Department of Pediatrics.			
48-	18/04/2022	GBT440-034	Sponsor: GBT (Subsidiary of Pfizer) CRO: IQVIA	An Open Label Extension Study of GBT440 Administered Orally to Patients with Sick Cell Disease who Have Participated in GBT440 Clinical Trials	III	1-Cairo University, Abu El Rich Hospital. 2-Ain Shams University Clinical Research Center (MASRI-CRC) 3-Alexandria University Clinical Research Center 4-Zagazig University Hospital, Department of Pediatrics.	Approved 02/08/2022 Early Termination by the sponsor 30/09/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor
49-	17/05/2022	F901318/032	Sponsor: F2G CRO: IQVIA	Open Label Single Arm Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to	IIb	1-Mansoura University Oncology center 2-Alexandria University,	Terminated (By Sponsor) 24/07/2022	Invasive Fungal Infection	(Pharmaceutical) Olorofim

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal



				Lomentospora Prolificans, Seedosporium Spp., Aspengillus Spp., & other Resistant Fungi in Patients Lacking Suitable Alternative		Clinical Research Center 3-Nasser Institute 4-Ain Shams University Clinical Research Center, (MASRI – CRC) 5-Air Force specialized Hospital 6-National Cancer Institute 7-Cairo University Kasr Al-Eini, Hospital			
50-	12/06/2022	CLSYN.1 702 (OASIS- 9)	Sponsor: Hamilton Health Science CRO: Clinmax	A 2x2 Factorial Randomized Controlled Trial of Colchicine and spironolactone in Patients With myocardial infarction/SYNER	III/IV	1-Mansoura University Hospital 2-Suez Canal University Hospital	Approved 24/07/2022 Completed 01/08/2024	STEMI/Non- STEMI Myocardial Infarction	(Pharmaceutical) Colchicine, Spironolactone/ matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				GY Stent Registry – Organization to Assess Strategies for Ischemic Syndromes 9		3-Fayoum General Hospital 4-Tamia Central Hospital 5-El Kharga Specialized Hospital 6-National Heart Institute			
51-	15/06/2022	20140106	Sponsor: Onyx Pharmace uticals (Subsidiar y of Amgen) CRO: IQVIA	Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Ib/II	1-Children's Cancer Hospital 57357	Approved 23/08/2022 Withdrawn 19/06/2023	Relapsed or Refractory Acute Lymphoplast ic Leukemia	(Pharmaceutical) Carfilzomib
52-	18/07/2022	AG348-C- 020	Sponsor: Agiros CRO: MCT	A Phase 2/3, Double-Blind, Randomized, Placebo- Controlled, Multicenter Study	II/III	1-Alexandria University Clinical Research Center	Approved 27/09/2022 Withdrawn 21/08/2023	Sickle Cell Disease	(Pharmaceutical) Mitapivat / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				to Evaluate the Efficacy and Safety of Mitapivat in Subjects with Sickle Cell Disease		2-Zagazig University Hospital 3-Cairo University Hospital 4-Mansoura University Hospital 5-Ain Shams University Clinical Research Center (MASRI-CRC)			
53-	26/07/2022	F901318/0041	Sponsor: F2G CRO: IQVIA	A Phase III, Adjudicator-Blinded, Randomised Study to Evaluate the Efficacy and Safety of Treatment with Olorofim Versus Treatment with Ambisome® Followed by Standard of Care (SOC) in Patients	III	1-Mansoura University Oncology Center 2-Alexandria University Clinical Research Center 3-Air Force specialized Hospital 4-Ain Shams University,	Approved 11/10/2022	Invasive Fungal Disease caused by Aspergillus species	(Pharmaceutical) Olorofim / Ambisome

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				with Invasive Fungal Disease (IFD) Caused by Aspergillus Species		Clinical Research Center (MASRI-CRC) 5-Zagazig University Hospital 6-National Cancer Institute 7-Cairo University Kasr Al Eini Hospital 8-Nasser Institute for Research and Treatment			
54-	27/07/2022	APD334-202	Sponsor: Arena Pharmaceuticals (Subsidiary of Pfizer)	A Multicenter Randomized Double Blinded Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severe Active	III	1-Alexandria University Clinical Research Center 2-Air Force Specialized Hospital 3-National Liver Institute 4-National Hepatology and Tropical	Approved 23/08/2022 Recruitment Completion Early Terminated by the sponsor 20/03/2025	Moderately to Severe Active Crohn's Disease	(Pharmaceutical) Etrasimod / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Crohn's Disease (Etrasimod)		Medicine Research Institute (NHTMRI) 5-Cairo University Kasr Al-Eini Hospital 6-Egyptian Liver Research Institute and Hospital 7-Ain Shams University Hospital 8-Theodor Bilharz Research Institute			
55-	07/08/2022	EFC17215 LEAP-2- MONO	Sponsor: Sanofi	A Phase 3, Multicenter, Multinational Randomized Double-Blind Double-Dummy, Active Comparator Study to Evaluate the Efficacy and	III	1-Alexandria University Hospital Clinical Research Center	Approved 24/10/2022	Gaucher Disease Type 3 (GD3)	(Pharmaceutical) Venglustat/ Cerezyme

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) who Have Reached Therapeutic Goals with Enzyme Replacement Therapy					
56-	15/08/2022	AG348-C-017	Sponsor: Agios CRO: MCT	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Non-Transfusion-Dependent Alpha-or Beta-Thalassemia (ENERGIZE)	III	1-Cairo University Hospital 2-Ain Shams University Clinical Research Center MASRI-CRC	Approved 02/11/2022 Withdrawn 26/06/2023	Non-Transfusion-Dependent Alpha or Beta Thalassemia	(Pharmaceutical) Mitapivat / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

57-	15/08/2022	AG348-C-018	Sponsor: Agiros CRO: MCT	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta- Thalassemia (ENERGIZE-T)	III	1-Cairo University Hospital 2-Ain Shams University Clinical Research Center MASRI-CRC	Approved 02/11/2022 Withdrawn 26/06/2023	Transfusion-Dependent Alpha or Beta Thalassemia	(Pharmaceutical) Mitapivat / matching placebo
58-	29/08/2022	4202-HEM-301	Sponsor: Forma Therapeutics CRO: MCT	An Adaptive, Randomized, Placebo-Controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease	III	1- Alexandria University Clinical Research Center 2-Zagazig University Hospital 3-Cairo University Hospital 4-Ain Shams University Clinical	Approved 11/12/2022 Recruitment Completion	Sickle Cell Disease	(Pharmaceutical) Etavopivat / matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						Research Center (MASRI-CRC)			
59-	29/09/2022	GO42784 LIDERA	Sponsor: Roche CRO: MCT	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer	III	1-Alexandria University Hospital 2-Medical Research Institute, Alexandria University 3-Mansoura University Hospital 4-Cairo University Kasr Al- Ainy Hospital 5-Ain Shams University Demerdash Hospital 6- Dar El Salam Cancer Hospital 7- Sohag Oncology Center	Approved 04/12/2022 Recruitment Completion	Estrogen Receptor-Po sitive, Her2- Negative Early Breast Cancer	(Pharmaceutical) Giredestrant / Physician Choice of Adjuvant Endocrine Monotherapy

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

60-	16/11/2022	(ACTIV-2D/A5407)	Sponsor: Shionogi CRO: IQVIA	A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared with Placebo in Non-Hospitalized Participants with COVID-19	III	1-National Hepatology and Tropical Medicine Research Institute 2-Ain Shams University Clinical Research Center (MASRI-CRC) 3-Alexandria University Clinical Research Center, 4-Air Force Specialized Hospital 5-National Institute for Chest Allergy and Diseases 6-Imbaba Fever Hospital	Approved 31/01/2023 Withdrawn 26/09/2023	Covid-19 treatment	(Pharmaceutical) S-217622 / matching placebo
61-	28/11/2022	RBSC2161	Sponsor: Salix	A Phase 2a Randomized,	Ila	1-Cairo University Abu	Approved 05/02/2023	Sickle Cell Disease	(Pharmaceutical)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			pharmaceuticals CRO: IQVIA	Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease		El Rich Hospital. 2-Ain Shams University Clinical Research Center (MASRI-CRC) 3-Zagazig University Hospital 4-Cairo University Hospital 5-Alexandria University Clinical Research Center	Withdrawn 06/11/2023		Rifaximin / matching placebo
62-	22/01/2023	AT/03A-017	Sponsor: Atea Pharmaceuticals CRO: Avicemer	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk	III	1- National Hepatology and Tropical Medicine Research Institute	Approved: 15/10/2023 Withdrawn 07/04/2024	COVID-19	(Pharmaceutical) Bemnifosbuvir/matching Placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Outpatients with COVID-19					
63-	13/02/2023	ENRICH-AF	Sponsor: Hamilton Health Science CRO: Clinmax	Edoxaban for Intracranial Haemorrhage Survivors with Atrial Fibrillation (ENRICH- AF) Edoxaban 60/30mg once daily	IV	1-Ain Shams University Clinical Research Center (MASRI-CRC) 2-Zagazig University Hospital 3-Fayoum General Hospital 4-Tanta University Hospital 5-Mansoura University Hospital 6-Ain Shams Specialized Hospital 7-Alexandria University Clinical Research Center	Approved 10/05/2023 Recruitment Completion	Atrial Fibrillation in patients with previous Intracranial Haemorrhage	(Pharmaceutical) Edoxaban

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						8-Assuit University Hospital			
64-	13/02/2023	GBT440-038	Sponsor: GBT (Subsidiary of Pfizer)	An Open-Label Extension Study of Voxelotor Administered Orally to Paediatric Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials	III	1-Alexandria University Clinical Research Center 2- Zagazig University Hospital 3-Cairo University, Abu El Rich Hospital. 4- Ain Shams University, Faculty of Medicine CRC (MASRI).	Approved 30/03/2023 IMP Dosing Pause 02/05/2024 Early Terminated by the Sponsor 26/09/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor
65-	01/03/2023	GN41851 FENHANCE	Sponsor: Roche	A Phase III Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group	III	1-Alexandria University- Clinical Research Center	Approved 26/4/2023 Withdrawn 11/01/2024	Relapsing multiple sclerosis	(Pharmaceutical) Fenebrutinib/ Teriflunomide/ matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide In Adult Patients with Relapsing Multiple Sclerosis. .					
66-	06/03/2023	1305-0023 (FIBRONE ER –ILD	Sponsor: Boehringer Ingelheim CRO: IQVIA	A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	III	1-Ain Shams University Clinical Research Center (MASRI-CRC) 2- Alexandria University Clinical Research Center 3- Air Force Specialized Hospital 4- Cairo University, Kasr Al Aini Hospital	Approved 01/06/2023 Withdrawn 17/01/2024	Progressive Fibrosing Interstitial lung diseases (PF-ILDs)	(Pharmaceutical) BI 1015550 / matching placebo
67-	06/03/2023	1305-0014	Sponsor: Boehringer	A Double Blind, Randomized,	III	1- Ain Shams University	Approved 01/06/2023	Idiopathic Pulmonary	(Pharmaceutical)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

		(FIBRON EER – IPF)	r Ingelheim CRO: IQVIA	Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Idiopathic Pulmonary Fibrosis (IPF)		Clinical Research Center (MASRI-CRC) 2- Alexandria University Clinical Research Center 3- Air Force Specialized Hospital 4- Cairo University, Kasr Al Ainy Hospital	Withdrawn 08/01/2024	Fibrosis (IPF)	BI 1015550 / matching placebo
68-	16/03/2023	4202- HEM-201	Sponsor: Forma Therapeuti cs CRO: MCT	A Phase 2 Open- Label Study to Evaluate Safety and Clinical Activity of FT- 4202 in Patients with Thalassemia or Sickle Cell Disease	II	1- Cairo University, Abu El-Rich Children Hospital. 2-Cairo University, Kasr Al Eini Hospital.	Approved 01/06/2023 Recruitment Completion	Thalassemia or Sickle Cell Disease	(Pharmaceutical) Etavopivat
69-	15/05/2023	EFC16035 (PERSEUS)	Sponsor: Sanofi	A Phase 3, Randomized,	III	1- Alexandria University	Approved 10/08/2023	Primary Progressive Multiple	(Pharmaceutical)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis		Clinical Research Center	Withdrawn 15/04/2024	Sclerosis	Tolebrutinib/ Matching Placebo
70-	14/03/2024	WO43571 HereDER A	Sponsor: Roche	A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy with Phesgo+ Taxane in Patients with Previously Untreated Her2- Positive, Estrogen Receptor-Positive	III	1- Sohag Oncology Center 2- Dar El Salam Cancer Hospital 3- National Cancer Institute	Approved 08/04/2024 Recruitment Completion	Previously Untreated Her2- Positive, Estrogen Receptor- Positive Locally- Advanced or Metastatic Breast Cancer	Pharmaceutical Giredestrant

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Locally-Advanced or Metastatic Breast Cancer					
71-	22/04/2024	1517-CL-1003	Sponsor: Astellas Pharma Global Developm ent CRO: MCT	A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease 1517-CL-1003	III	1- Cairo University Children's Hospital 2- Ain Shams University Hospital 3- Alexandria University Hospital	Approved 10/7/2024 Withdrawn 26/09/2024	Anemia in Pediatric Patients with Chronic Kidney Disease	Pharmaceutical Roxadustat
72-	05/06/2024	M23-698	Sponsor: Abbvie	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in	III	1- Ain Shams University CRC (MASRI) 2- Air Force Specialized Hospital	Approved 07/08/2024 Withdrawn 09/04/2025	Moderate to Severe Hidradenitis Suppurativa	Pharmaceutical Upadacitinib

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy M23-698		3- Alexandria University CRC			
73-	16/12/2024	DAY101-002	Sponsor: Day One Biopharmaceuticals CRO: MCT	A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	III	1- Children Cancer Hospital Egypt-57357	Approved 20/02/2025	Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	Pharmaceutical Tovorafenib

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

74-	29/01/2025	NN7535-7822 FLORAL	Sponsor: Forma Therapeutics CRO: IQVIA	An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of Etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study	III	1- Alexandria University Clinical Research Center (PI: Prof. Hoda Hassab) 2-Alexandria University Clinical Research Center (PI: Prof. Ashraf El Ghandour) 3-Zagazig University Hospital 4-Kasr Al Aini Hospital, Cairo University 5-Ain Shams University Clinical Research Center (MASRI-CRC) 6- Abu El Rich Al Mounira Children	Approved 10/04/2025 Recruiting	Adults, adolescents and children who have sickle cell disease or thalassaemia	Pharmaceutical (Etavopivat)
-----	------------	-----------------------	--	---	-----	---	--	---	-----------------------------

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						Hospital, Cairo University			
75-	16/06/2025	ID-064A301 (OPUS-1)	Sponsor: Idorsia Pharmaceuticals CRO: RAY	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects with Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy (OPUS-1)	III	1- Air Force Specialized Hospital 2- Alexandria University Clinical Research Center 3- Ain Shams University Clinical Research Center (MASRI-CRC)	Approved 10/08/2025	Adult Subjects with Moderate to Severe Systemic Lupus Erythematosus	Pharmaceutical (Cenerimod)
76-	24/07/2022	MD-004	Sponsor: Ezz Medical Industries	Open labelled non randomized self-controlled study to evaluate the safety	III (pivotal)	1-Kasr Al-Aini university Hospital	Approved 28/08/2022 Suspended	Hospitalized mechanically ventilated patients	Medical device (Ezvent)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			CRO: Dataclin	and performance of Ezvent in hospitalized mechanically ventilated patients			01/01/2024 Resumed 13/01/2024 Completed 03/06/2025		
77-	15/05/2022	COAV101 B12301	Sponsor: Novartis CRO: MCT	A randomized sham controlled double –blind study to evaluate the efficacy and safety of intrathecal (IT) QAV101 in patients with later onset type 2 spinal muscular atrophy (SMA) who are ≥ 2 to <18 years of age, treatment naïve sitting and never ambulatory	III	1-Department of Neurology, Ain Shams University Specialized Hospital.	Approved 02/08/2022 Early terminated (by sponsor) 18/12/2023	type 2 spinal muscular atrophy (SMA)	Innovative QAV101 (Zolgensma) (Onasemnogene abeparvovec)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

78-	06/06/2023	Urso-003	Sponsor: Minapharm CRO: Dataclin	Multi-Center, randomized, control, phase IV trial to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Disease Patients	IV	1-Clinical Research Center, Air force specialized Hospital 2-National Hepatology and Tropical Research Institute (NHTMRI)	Approved 18/09/2023 Suspended (Recruitment suspension) 26/11/2024	Compensated Chronic Liver Disease Patients	Innovative Ursoplus® capsules/ Ursofalk® capsules
79-	06/06/2023	Cipro-001	Sponsor: Minapharm, CRO: Nagy Research	Single center, Open Label, controlled Study to assess the safety & efficacy of Oral Ciprodiazole ® Tablets (Ciprofolxacin/ Metronidazole) versus currently used Ciprofloxacin Tablets &	IV	1- General Surgery department, Menoufia University Hospital.	Suspended 12/09/2023	Pelvi- abdominal infections and following IV antibiotics in post- operative period, for pelvi- abdominal surgeries or	Innovative Ciprodiazole ® Tablets (Ciprofolxacin/ Metronidazole)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions				acute conditions	
80-	15/05/2023	Sub-Thromb-001	Sponsor: Minapharm	A Prospective, Single- Center, Phase IV Interventional, Single Arm Trial for the Evaluation of subcutaneous recombinant Hirudin 15 mg (RB variant) in prophylaxis of Deep Vein Thrombosis (DVT) post major orthopedic operations	IV	1- Department of Orthopedics and Trauma Surgery, El-Hadra University Hospital	Withdrawn 28/08/2023	prophylaxis of Deep Vein Thrombosis (DVT) post major orthopedic operations	Innovative Thrombex (recombinant Hirudin)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal



81-	24/10/2023	GRC/NE-CV/EG/39/IV	Sponsor: Nerhadou International CRO: Genuine research center	A prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment in Egyptian Patients with Essential Hypertension	IV	1- Department of General Internal Medicine , Beni-Suef University Hospital 2- Department of Cardiology and vascular medicine, Fayoum University Hospital	Approved 10-3-2024 Terminated by sponsor 13/05/2025	Essential Hypertension	Innovative Nerkardou (Bisoprolol) Oral dispersible film
-----	------------	--------------------	---	---	----	---	--	------------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal